GLPBio

Gossypol

Catalog No.: GN10082Purity:>99.50%Synonyms: BL 193, (±)-Gossypol, NSC 56817, NSC 624336, Pogosin
Gossypol is a lipid-soluble polyphenolic compound extracted from the cotton plant with antifertility, antioxidant, and anticancer properties.

Los productos son exclusivamente para uso en investigación. No aptos para uso humano. No vendemos a pacientes.


Gossypol
Cas No.: 303-45-7
10mM (in 1mL DMSO)In Stock
$31.00
1
50mgIn Stock
$28.00
1
100mgIn Stock
$49.00
1

Citas (Citations)

Actualmente no hay citas disponibles para este producto. A continuación se muestran publicaciones seleccionadas que citan productos GlpBio.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Descripción (Description)

Gossypol is a lipid-soluble polyphenolic compound extracted from the cotton plant with antifertility, antioxidant, and anticancer properties [1]. Gossypol can block the release and utilization of ATP in sperm cells, reduce the contents of cytoskeleton and microtubule β-tubulin in spermatogenic cells and sperm cells, and inhibit the calcium influx in the cell membrane of sperm cells, as well as the activities of Mg-ATPase and Ca-Mg-ATPase[2]. Gossypol has been widely used to inhibit the proliferation of various tumor cells and induce mitochondrial dysfunction in cancer cells [3].

In vitro, Gossypol treatment for 12 hours significantly promoted the death of Jurkat cells overexpressing Bcl-2 and Jurkat cells overexpressing Bcl-XL, with IC50 values of 18.1µM and 22.9µM, respectively[4]. Treatment with 80 µM Gossypol for 24 hours significantly induced cell necrosis in U266 cells and enhanced the production of reactive oxygen species and DNA damage[5]. Treatment with 20µM Gossypol for 24 hours significantly induced apoptosis in H1975 cells and inhibited the phosphorylation of EGFR as well as the downstream signaling pathways[6].

In vivo, Gossypol treatment via intraperitoneal injection at a dose of 10mg/kg/day for 4 weeks significantly inhibited tumor growth in the MDA-MB-468 xenograft mouse model and reduced VEGF-mediated angiogenesis[7]. A single intraperitoneal injection of 40mg/kg of Gossypol for 8 hours significantly alleviated lung injury in mice induced by lipopolysaccharide (LPS) and inhibited the production of cytokines[8].

References:
[1] Keshmiri-Neghab H, Goliaei B. Therapeutic potential of gossypol: an overview[J]. Pharmaceutical Biology, 2014, 52(1): 124-128.
[2] Gadelha I C N, Fonseca N B S, Oloris S C S, et al. Gossypol toxicity from cottonseed products[J]. The Scientific World Journal, 2014, 2014(1): 231635.
[3] Paunovic D, Rajkovic J, Novakovic R, et al. The potential roles of gossypol as anticancer agent: Advances and future directions[J]. Chinese Medicine, 2023, 18(1): 163.
[4] Oliver C L, Miranda M B, Shangary S, et al. (−)-Gossypol acts directly on the mitochondria to overcome Bcl-2-and Bcl-XL-mediated apoptosis resistance[J]. Molecular cancer therapeutics, 2005, 4(1): 23-31.
[5] Xu R, Tian E, Tang H, et al. Proteomic analysis of gossypol induces necrosis in multiple myeloma cells[J]. BioMed Research International, 2014, 2014(1): 839232.
[6] Wang Y, Lai H, Fan X, et al. Gossypol inhibits non-small cell lung cancer cells proliferation by targeting EGFRL858R/T790M[J]. Frontiers in pharmacology, 2018, 9: 728.
[7] Xiong J, Li J, Yang Q, et al. Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer[J]. Breast Cancer Research, 2017, 19(1): 27.
[8] Liu Z, Yang Z, Fu Y, et al. Protective effect of gossypol on lipopolysaccharide-induced acute lung injury in mice[J]. Inflammation research, 2013, 62(5): 499-506.

Protocolo (Protocol)

Cell experiment [1]:

Cell lines

H1975 cells

Preparation Method

H1975 cells were grown in RPMI-1640 medium with 10% (v/v) fetal bovine serum (FBS), antibiotic/antimycotic solution at 37°C in 5% CO2/atmosphere. Cells were seeded in 96-well plates at a density of 3×103 cells and cultured overnight. After 72h of treatment with different concentrations of Gossypol (0, 10, 20, 30, 40, and 50µM), the cell viability was measured.

Reaction Conditions

0, 10, 20, 30, 40, and 50µM; 72h

Applications

Gossypol treatment significantly inhibited the cell viability of H1975 cells in a dose-dependent manner.
Animal experiment [2]:

Animal models

Male BALB/c mice

Preparation Method

Male BALB/c mice (6 weeks old; 18-22g) were housed singly in a standard environment with food and water ad libitum. Gossypol (40mg/kg) was given by intraperitoneal injection (i.p.). Blank control and LPS group mice were given an equal volume of distilled water by i.p. 1h later, mice were slightly anesthetized with an inhalation of diethyl ether, 10μg of LPS in 50μl PBS was instilled intranasally (i.n.) to induce lung injury. Blank control group mice were given a 50μl PBS by i.n. without LPS. All the mice were alive after 7h LPS treatment. The mice were killed by exsanguination at 7h after the administration of LPS. Collection of bronchoalveolar lavage fluid (BALF) for analysis.

Dosage form

40mg/kg for once; i.p.

Applications

Gossypol treatment significantly reduced the production of inflammatory cytokine in in the BALF of LPS-induced mice.

References:
[1] Wang Y, Lai H, Fan X, et al. Gossypol inhibits non-small cell lung cancer cells proliferation by targeting EGFRL858R/T790M[J]. Frontiers in pharmacology, 2018, 9: 728.
[2] Liu Z, Yang Z, Fu Y, et al. Protective effect of gossypol on lipopolysaccharide-induced acute lung injury in mice[J]. Inflammation research, 2013, 62(5): 499-506.

Documentos del producto (Product Documents)

Purity:>99.50%Appearance:A solid

Propiedades químicas (Chemical Properties)

N.º CAS
303-45-7
Sinónimos
BL 193, (±)-Gossypol, NSC 56817, NSC 624336, Pogosin
Nombre químico
7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde
SMILES
CC1=C(C(=C2C(=C1)C(=C(C(=C2C=O)O)O)C(C)C)O)C3=C(C=C4C(=C3O)C(=C(C(=C4C(C)C)O)O)C=O)C
Fórmula molecular
C30H30O8
Peso molecular
518.55
Solubilidad
≥ 25.95mg/mL in DMSO
Almacenamiento
4°C, protect from light
Consejos generales
Seleccione un disolvente adecuado según los datos de solubilidad del producto. Una vez preparada, divida la solución madre en alícuotas para evitar ciclos repetidos de congelación y descongelación.
Utilice las soluciones madre en un plazo de 6 meses si se conservan a -80°C, o de 1 mes si se conservan a -20°C.
Para mejorar la solubilidad, caliente el tubo a 37°C y soníquelo durante un periodo adecuado.
Condiciones de envío
Las muestras de evaluación se envían con acumuladores de frío. Los demás tamaños se envían a temperatura ambiente o, previa solicitud, con acumuladores de frío.

Calculadoras (Calculators)Molaridad / Dilución / Peso molecular / Conversión de unidades / Formulación in vivo / Solubilidad

g/mol

Reviews

Review for Gossypol

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%